Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, discusses the occurrence of extramedullary disease (EMD) in multiple myeloma and the challenges it poses. EMD, occurring when malignant cells escape the bone marrow, can be classified as showing paraskeletal or extramedullary organ involvement. While EMD incidence at the time of myeloma diagnosis is low, it occurs more commonly in relapsed/refractory disease. Dr Jurczyszyn talks on investigations into the prognosis of patients with EMD, including cutaneous and central nervous system involvement. He also comments on the need for improved treatment options, noting the recently demonstrated promise of melflufen in the HORIZON study (NCT02963493). This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.